Societies
FDA Approval of Zidesamtinib for ROS1-Positive NSCLC – IASLC
IASLC/LinkedIn

FDA Approval of Zidesamtinib for ROS1-Positive NSCLC – IASLC

International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:

“What does the FDA approval of zidesamtinib mean for patients with ROS1-positive NSCLC?

In this latest Lung Cancer Considered episode, Dr. Stephen Liu is joined by Dr. Alexander Drilon and Dr. Rosario Charo Garcia Campelo to discuss:

  • Key findings from the ARROS1 trial
  • The efficacy and safety profile of zidesamtinib
  • CNS activity and clinical implications
  • Where this new therapy may fit into current and future treatment strategies

Tune in.”

Discover more:

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLCFDA Approval of Zidesamtinib for ROS1-Positive NSCLC - IASLC

Alexander Drilon cancer FDA IASLC Lung cancer NSCLC OncoDaily Oncology Rosario Charo Garcia Campelo Stephen Liu zidesamtinib